X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Getting Immunotherapy Work In Case of Pancreatic Cancer

Content Team by Content Team
30th January 2023
in Drug Development, News

One of the latest studies that takes into account the tumour microenvironment of pancreatic cancer puts forth the cause that tumour cells are resistant to immunotherapy, resulting in new strategies for treatment.

The study, which is led by Johns Hopkins Kimmel Cancer Center researchers, is the latest when it comes to the ongoing platform trial, which was formed in 2015 in order to take into account immunotherapy treatment before and after the surgery in patients with pancreatic cancer. The platform helps the researchers use the data generated by the trial to progress the immunotherapy development for pancreatic cancer in the same trial, according to Lei Zheng, MD, Ph.D.

It should be taken into account that pancreatic cancer suppresses the immune response of the body and also prevents its immune effector cells like the T cells from thwarting tumour cells, which researchers term a cold microenvironment. In this particular platform trial, scientists gained key information on the microenvironment of the cells that are in and around the tumour and trigger the immune response.

There were two forms of treatment that were known to stimulate the T cells of the body to attack cancer either alone or in a group that were researched, including anti-PD-1 immunotherapy, which restricts the immune checkpoint that these cancer cells make use of to turn off cancer’s immune response. The other immunotherapy study was GVAX, which happens to be a therapeutic vaccine that can stimulate the immune system of the patient so as to attack the cancer.

There were, however, two prominent defects that were found in the microenvironment of the pancreatic cancer tumor. The first point was that T cells are exhausted and aren’t sufficiently active, and the second element is that myeloid cells go on to barge the microenvironment and prevent T cells from triggering against the cells of pancreatic cancer even when they have been treated with GVAX as well as anti-PD-1 immunotherapy.

According to Zheng, a significant element of the myeloid cells known as neutrophils created by the immune cells to thwart injection is taken over by pancreatic cancer cells in order to suppress the activation of T cells.

Because of these findings, the researchers have already begun testing two novel treatment strategies which are anti-CD137 to activate T cells and anti-IL-8 antibody treatment tagging along with anti PD-1 immunotherapy. As per Zheng, they have seen a promising activity, which they believe will enhance the disease-free survival rate in patients after the surgery.

Previous Post

Monoclonal Antibodies Ideal Against Malaria- Suggests Study

Next Post

FDA Comes With A Research Map Concerning Biosimilars Program

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Next Post

FDA Comes With A Research Map Concerning Biosimilars Program

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In